Author Contributions: Dr Kastrati had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Kastrati, Schömig.
Acquisition of data: Mehilli, Antoniucci.
Analysis and interpretation of data: Ndrepepa, Kastrati.
Drafting of the manuscript: Ndrepepa, Kastrati.
Critical revision of the manuscript for important intellectual content: Mehilli, Antoniucci, Schömig.
Statistical analysis: Ndrepepa, Kastrati.
Obtained funding: Schömig.
Administrative, technical, or material support: Mehilli, Antoniucci, Schömig.
Study supervision: Antoniucci, Schömig.
Financial Disclosures: None reported.
Funding/Support: The primary trial was supported by grants KKF 10-02 and KKF 04-03 from Deutsches Herzzentrum, Munich, Germany, as well as by unrestricted research grants from Lilly Deutschland GmbH, Bad Homburg, Germany, and Guidant Advanced Cardiovascular Systems Inc, Santa Clara, California.
Role of the Sponsor: The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: Stefanie Schulz, MD, Deutsches Herzzentrum, Munich, Germany, provided help with the statistical analysis, for which she received no compensation. We appreciate the contributions of all the investigators of the BRAVE-2 trial.